Literature DB >> 23446806

Proposal for a predictive model of erectile function after permanent (125)I prostate brachytherapy for localized prostate cancer.

E Huyghe1, B Delaunay, P Njomnang Soh, M Delannes, M Walschaerts, D Delavierre, M Soulie, J M Bachaud.   

Abstract

To determine the risk factors for EDin men treated by prostate brachytherapy (PB) for localized prostate cancer and to propose a model to predict post-implant erectile function. Out of a series of 270 sexually active men treated by PB, 241 (89%) (mean age=66 years (range, 43-80)) accepted to participate in a mail-based study on erectile function. The risk factors for erectile dysfunction were determined by regression analysis and a predictive model was proposed. The performance of the model was determined in this population and subsequently verified in a population of 50 men treated by PB in another treatment center. The risk factors for ED after PB were age, the pre-implant IIEF score and prostate volume. In the studied population, the final model to predict a post-treatment IIEF-5 score, using these factors, had a sensitivity of 69% and a specificity of 68% associated to an area under the ROC curve (AUC) of 0.75. The same performance was obtained in another treatment center. Age, pre-implant IIEF-5 score and prostate volume may be used to predict post-implant erectile function in patients treated by PB.

Entities:  

Mesh:

Year:  2013        PMID: 23446806     DOI: 10.1038/ijir.2013.3

Source DB:  PubMed          Journal:  Int J Impot Res        ISSN: 0955-9930            Impact factor:   2.896


  1 in total

1.  Evaluation of erectile potency and radiation dose to the penile bulb using image guided radiotherapy in the CHHiP trial.

Authors:  Julia Murray; Sarah Gulliford; Clare Griffin; Anna Wilkins; Isabel Syndikus; John Staffurth; Miguel Panades; Christopher Scrase; Chris Parker; Vincent Khoo; Jamie Dean; Helen Mayles; Philip Mayles; Simon Thomas; Olivia Naismith; Helen Mossop; Clare Cruickshank; Emma Hall; David Dearnaley
Journal:  Clin Transl Radiat Oncol       Date:  2019-12-31
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.